Aa
FDA review of oral MS drug FTY720 extended
For those who are keeping their eyes on the new oral drugs:
"Novartis announced today that the US Food and Drug Administration (FDA) has extended by three months, to September 2010, its review period for the regulatory approval of FTY720 (fingolimod [now known as Gilenia]). FTY720 once-daily 0.5 mg has the potential to be the first oral therapy for relapsing multiple sclerosis (MS)."
http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/1309
sho
"Novartis announced today that the US Food and Drug Administration (FDA) has extended by three months, to September 2010, its review period for the regulatory approval of FTY720 (fingolimod [now known as Gilenia]). FTY720 once-daily 0.5 mg has the potential to be the first oral therapy for relapsing multiple sclerosis (MS)."
http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/1309
sho
Ditto to what Alex said about this being awesome news. I have been wondering the status of the FDA review and glad to hear they extended the deadline for the review. Hopefully that means they are liking what they are seeing and that is great news for those of us who want to try it.
Thanks as usual, Sho, for keeping us in the loop.
Julie
Thanks as usual, Sho, for keeping us in the loop.
Julie
Have an Answer?
You are reading content posted in the Multiple Sclerosis Community
Top Neurology Answerers
Australia
ON
Queensland, Australia
Queen Creek, AZ
Find out how beta-blocker eye drops show promising results for acute migraine relief.
In this special Missouri Medicine report, doctors examine advances in diagnosis and treatment of this devastating and costly neurodegenerative disease.
Here are 12 simple – and fun! – ways to boost your brainpower.
Discover some of the causes of dizziness and how to treat it.
Discover the common causes of headaches and how to treat headache pain.
Two of the largest studies on Alzheimer’s have yielded new clues about the disease
